Acelrx Pharmaceuticals (ACRX)

Acelrx (ACRX) Income Statement


Acelrx Income Statement

Last quarter (Q1 2023), Acelrx's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q1, Acelrx's net income was $10.72M. See Acelrx’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 1.33M$ 1.77M$ 2.82M$ 5.42M$ 2.29M$ 2.15M
Cost of Revenue
$ 6.26M$ 2.59M$ 3.75M$ 6.03M$ 6.81M$ 3.98M
Gross Profit
$ -5.97M$ -2.59M$ -935.00K$ -616.00K$ -4.52M$ -1.82M
Operating Expense
$ 16.88M$ 36.10M$ 35.03M$ 40.35M$ 49.69M$ 33.90M
Operating Income
$ -22.85M$ -38.70M$ -35.97M$ -40.96M$ -54.20M$ -35.73M
Net Non Operating Interest Income Expense
$ 5.42M$ 84.40M$ 871.00K$ 588.00K$ 968.00K$ -11.42M
Other Income Expense
$ 70.39M$ -1.77M----
Pretax Income
$ 67.16M$ 47.77M$ -35.09M$ -40.38M$ -53.24M$ -47.15M
Tax Provision
$ 13.00K$ 13.00K$ 5.00K$ 4.00K$ 3.00K$ 2.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ 104.06M$ 84.67M$ -35.10M$ -40.38M$ -53.24M$ -47.15M
Basic EPS
$ 13.41$ 5.73$ -5.80$ -0.47$ -0.67$ -0.81
Diluted EPS
$ 13.34$ 5.72$ -5.80$ -0.47$ -0.67$ -0.81
Basic Average Shares
$ 22.12M$ 7.39M$ 5.99M$ 85.26M$ 79.18M$ 58.41M
Diluted Average Shares
$ 33.04M$ 7.41M$ 5.99M$ 85.26M$ 79.18M$ 58.41M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 23.15M$ 38.70M$ 38.78M$ 46.38M$ 56.49M$ 37.88M
Net Income From Continuing And Discontinued Operation
$ 48.28M$ 47.76M$ -35.10M$ -40.38M$ -53.24M$ -47.15M
Normalized Income
$ 68.81M-$ -35.10M$ -40.38M$ -53.24M$ -47.15M
Interest Expense
$ 574.00K-$ 2.29M$ 3.31M$ 2.54M$ 12.56M
$ 62.40M$ -36.63M$ -32.80M$ -37.07M$ -50.70M$ -34.59M
$ 63.98M$ -34.59M$ -30.83M$ -35.22M$ -49.03M$ -34.01M
Currency in USD

Acelrx Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis